Abstract
In order to develop melanoma-targeted in situ peptide vaccine immunotherapy, magnetite nanoparticles were conjugated with a melanogenesis substrate, N-propionyl cysteaminylphenol (NPrCAP). Magnetite nanoparticles introduced thermotherapy which caused non-apoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF). NPrCAP was expected to develop a melanoma-targeted therapeutic drug because of its selective incorporation into melanoma cells and production of highly reactive free radicals, that result in not only oxidative stress but also apoptotic cell death by reacting with tyrosinase.
Highlights
Management of metastatic melanoma is extremely difficult challenge for physicians and scientists
In order to develop melanoma-targeted in situ peptide vaccine immunotherapy, magnetite nanoparticles were conjugated with a melanogenesis substrate, N-propionyl cysteaminylphenol (NPrCAP)
We provide evidence that melanoma-targeted in situ peptide vaccine immunotherapy has been successfully developed by conjugation of magnetite nanoparticles with a chemically modified melanogenesis substrate, and that a novel melanomatargeted chemo-thermo-immunotherapy (CTI Therapy) is provided for patients suffering from advanced metastatic
Summary
Management of metastatic melanoma is extremely difficult challenge for physicians and scientists. N-propionyl and N-acetyl derivatives of 4S-cysteaminylphenol (NPrand NAcCAP) were synthesized, and found to possess cytotoxic effects on in vivo and in vitro melanomas through the oxidative stress that derives from production of cytotoxic free radicals [17,18,19,20,21]. Based upon these rationales, we provide evidence that melanoma-targeted in situ peptide vaccine immunotherapy has been successfully developed by conjugation of magnetite nanoparticles with a chemically modified melanogenesis substrate, and that a novel melanomatargeted chemo-thermo-immunotherapy (CTI Therapy) is provided for patients suffering from advanced metastatic. Conjugation of Magnetite Nanoparticles with Melanogenesis Substrate, NPrCAP Provides Melanoma Targeted, in Situ Peptide Vaccine Immunotherapy through HSP Production by Chemo-Thermotherapy melanoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
